Fig. 7

Pre-treatment with pladienolide B in vitro impairs the onset/formation of GBM tumors in vivo and reduces colony and tumorsphere formation in vitro. a Generation of a preclinical-xenograft GBM model by inoculating U-87 MG cells previously pre-treated with pladienolide B in vitro for 24 h (n = 6) and 48 h (n = 6) compared with control-treated cells. b Average tumor volume of control-treated vs. pladienolide B-treated cells [(c) comparison of tumor volume between xenograft GBM-model with pre-treated cells for 48 h vs. 24 h]. d Average weight of control-treated vs. pladienolide B-treated cells. e Images of each tumor at the moment of sacrifice are shown individually. f 2D- and 3D-micro-CT imaging of a representative preclinical-xenograft GBM model hosting cells pre-treated for 24 h and 48 h with pladienolide B. g Particles per well using the colony formation assay after pladienolide B treatment in vitro (24 h and 48 h) in U-87 MG and U-118 MG cells (n = 3; representative images of colonies are included). h Number of tumorspheres per well using the tumorsphere formation assay after pladienolide B treatment in vitro (24 h and 48 h) in U-87 MG and U-118 MG cells (n = 3; representative images of tumorspheres formation are also included). Asterisks (*P < 0.05; **P < 0.01; ***P < 0.001) indicate statistically significant differences across different conditions